- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Joseph Alvarnas, MD, Discusses Biosimilar Use at City of Hope
Joseph Alvarnas, MD, a recent presenter at the Association of Community Cancer Centers annual meeting, discussed efforts to implement biosimilars at City of Hope, a clinical research center, hospital, and graduate medical school in Duarte, California.
Joseph Alvarnas, MD, is a hematologist and oncologist and an expert in bone marrow and stem cell transplantation at City of Hope in Duarte, California, where he serves also as vice president of Government Affairs and senior medical director for Employer Strategy. He is also a clinical professor in the Department of Hematology and Hematopoietic Cell Transplantation. He spoke with Tony Hagen, senior editor for The Center for Biosimilars®, about biosimilar use at his institution.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.
